Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$1.27B |
| 2 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$706M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$439M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$413M |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$272M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Weyerhaeuser
WY
|
+$431M |
| 2 |
Walt Disney
DIS
|
+$223M |
| 3 |
VXX
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
|
+$213M |
| 4 |
Halliburton
HAL
|
+$211M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$204M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.24% |
| 2 | Financials | 5.68% |
| 3 | Healthcare | 5.62% |
| 4 | Consumer Discretionary | 5.04% |
| 5 | Industrials | 3.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
CALL
Thermo Fisher Scientific
TMO
$220B
| $18.4M | 0.01% |
75,200
+24,300
| +48% | +$5.59M |
|
|
CLR
902
PUT
DELISTED
CONTINENTAL RESOURCES INC.
CLR
| $18.3M | 0.01% |
268,400
+54,300
| +25% | +$3.43M |
|
903
Nucor
NUE
$62.1B
| $18.3M | 0.01% |
288,108
+53,951
| +23% | +$3.45M |
|
904
Eastman Chemical
EMN
$8.42B
| $18.2M | 0.01% |
190,643
-64,985
| -25% | -$6.44M |
|
905
Hartford Financial Services
HIG
$39.3B
| $18.2M | 0.01% |
364,027
-112,891
| -24% | -$5.8M |
|
906
PUT
Kroger
KR
$34.8B
| $18.1M | 0.01% |
623,200
+271,700
| +77% | +$8.09M |
|
907
Akamai
AKAM
$15.9B
| $18.1M | 0.01% |
247,047
-49,812
| -17% | -$3.74M |
|
908
Canadian Pacific Kansas City
CP
$80.5B
| $18M | 0.01% |
424,135
+63,295
| +18% | +$2.53M |
|
909
PUT
HF Sinclair
DINO
$14.5B
| $18M | 0.01% |
257,100
+67,700
| +36% | +$4.78M |
|
910
CALL
RH
RH
$3.71B
| $17.9M | 0.01% |
136,900
+13,400
| +11% | +$1.88M |
|
|
WCG
911
DELISTED
Wellcare Health Plans, Inc.
WCG
| $17.9M | 0.01% |
55,819
+45,851
| +460% | +$13M |
|
912
PUT
Universal Display
OLED
$4.19B
| $17.9M | 0.01% |
151,700
-13,200
| -8% | -$1.45M |
|
|
913
HF Sinclair
DINO
$14.5B
| $17.9M | 0.01% |
255,674
+73,023
| +40% | +$5.15M |
|
914
Raymond James Financial
RJF
$34B
| $17.9M | 0.01% |
290,972
-36,682
| -11% | -$2.26M |
|
|
IPG
915
DELISTED
Interpublic Group of Companies
IPG
| $17.8M | 0.01% |
780,023
-11,405
| -1% | -$258K |
|
916
PUT
Abbott
ABT
$187B
| $17.8M | 0.01% |
243,100
+101,400
| +72% | +$6.66M |
|
|
ANSS
917
DELISTED
Ansys
ANSS
| $17.8M | 0.01% |
95,429
+8,430
| +10% | +$1.51M |
|
918
CALL
Sarepta Therapeutics
SRPT
$1.77B
| $17.8M | 0.01% |
110,300
-98,300
| -47% | -$13.4M |
|
919
CALL
Eli Lilly
LLY
$1.06T
| $17.8M | 0.01% |
165,900
-71,100
| -30% | -$7.11M |
|
|
AABA
920
PUT
DELISTED
Altaba Inc
AABA
| $17.8M | 0.01% |
261,100
-1,552,600
| -86% | -$109M |
|
|
AIMC
921
CALL
DELISTED
Altra Industrial Motion Corp
AIMC
| $17.8M | 0.01% |
+430,000
| New | +$18M |
|
922
Gartner
IT
$11.7B
| $17.8M | 0.01% |
112,035
+15,013
| +15% | +$2.18M |
|
923
CALL
Lam Research
LRCX
$390B
| $17.7M | 0.01% |
1,169,000
-459,000
| -28% | -$7.84M |
|
924
Nektar Therapeutics
NKTR
$2.58B
| $17.6M | 0.01% |
19,290
-7,610
| -28% | -$6.5M |
|
925
PUT
United Rentals
URI
$72.4B
| $17.6M | 0.01% |
107,500
-50,500
| -32% | -$7.86M |
|
Similar funds
Barclays's Q3 2018 Portfolio in Review
As of Q3 2018, Barclays held 7,740 positions worth $144B, up 24% from $116B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Barclays deployed $22.2B of net new capital in Q3 2018, opening 680 new positions and adding to 3,884 existing holdings. Its largest new stake was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.
By sector, the portfolio is most concentrated in Technology at 8.2% of assets, up from 7.4% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Weyerhaeuser, an estimated $431M trimmed.
- Barclays's largest Q3 2018 buy was iPath Series B S&P GSCI Crude Oil ETN: 5,000,000 shares worth $75.7M.
- Barclays added most to Fortive in Q3 2018, an estimated $1.27B increase.
- Barclays's biggest Q3 2018 reduction was Weyerhaeuser, cutting an estimated $431M.
- Barclays fully exited Validus Hold Ltd in Q3 2018, selling an estimated $71M.
- Barclays's ten largest holdings make up 31% of its $144B portfolio in Q3 2018.
- Barclays opened 680 new positions and closed 408 in Q3 2018.
- Barclays's portfolio value rose 24% quarter-over-quarter to $144B.
Based on Barclays's 13F filing for Q3 2018, filed 14 Nov 2018.